Onesource Specialty Pharma Ltd.

OneSource gets single FDA observation, PAT collapse looms larger

A routine US FDA inspection at its Bengaluru sterile facility ended with one observation. A benign outcome, but with profit after tax down 95.3%, the agency finding is not the main worry.